Prion diseases;Les maladies du prion

Revue Neurologique

Volumn 158, Issue 10 I, 2002, Pages 998-1007

  Warter, J M ^a   Steinmetz, G ^a   Mohr, M ^a   Tranchant, C ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; NUCLEIC ACID; PRION PROTEIN;

BOVINE SPONGIFORM ENCEPHALOPATHY; CATTLE; CONFORMATIONAL TRANSITION; CREUTZFELDT JAKOB DISEASE; FATAL FAMILIAL INSOMNIA; FOOD CONTAMINATION; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; KURU; PATHOGENESIS; PRION DISEASE; REVIEW; SCRAPIE;

BRAIN; HUMANS; PRION DISEASES; PRPC PROTEINS;

EID: 0036808246     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Adjou KT, Demaimay R, Deslys JP, et al., (1999). MS-8209, a water soluble amphotericin B derivative, affects both scrapie agent replication an PrPres accumulation in Syrian hamster scrapie. J Virol 80: 1079-85.
2. Alper T, Cramp WA, Haig DA, Clarke MC. (1967). Does the agent of scrapie replicate without nucleic acid? Nature 214: 764-66.
3. Beringue V, Adjou K.T, Lamoury F, et al., (2000). Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J Virol 74: 5432-40.
4. Brandel JP, Beaudry P, Delasnerie-Laupretre N, Laplanche JL. (1999). Maladie de Creutzfeldt-Jakob: Valeur diagnostique de la detection de la protéine 14-3-3 et du dosage de la NSE dans le liquide céphalo-rachidien. Rev Neurol 55: 148-51.
5. Brown P, Cathala F, Castaigne P, Gajdusek C. (1986). Clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 20: 597-602.
6. Bueler H, Fischer M, Lang Y, et al., (1992). Normal development and behaviour of mice lacking the neuronal cell surface PrP. Nature 256: 577-582.
7. Bueler H, Aguzzi A, Sailer A, et al., (1993). Mice devoid of PrP are resistant to scrapie. Cell 7: 1339-47.
8. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF. (2001). CSF detection of the 14-3-3 in unselected patients with dementia. Neurology 56: 1528-33.
9. Caspi S, Halimi M, Yanai A, Sasson SS, Taraboulos A, Gabizon R. (1998). The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 273: 3484-9.
10. Caughey B, Raymond GJ. (1993). Sulfated polyanion inhibition of scrapie-associated Prp accumulation in cultured cells. J Virol 67: 643-50.
11. Caughey WS, Raymond LD, Horiuchi M, Caughey B. (1998). Inhibition of protease-resistant prion protein formation by porphyrins and phtalocyanines. Proc Natl Acad Sci USA 95: 12117-22.
12. Collinge J, Whittington MA, Sidle KC, et al., (1994). Prion protein is necessary for normal synaptic function. Nature 370: 295-97.
13. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. (1996). Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383 685-90.
14. Demaerel P, Heiner L, Robberecht W, Sciot R, Wilms G. (1999). Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 52: 205-8.
15. Demaimay R, Adjou K, Lasmezas C et al., (1994). Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol 75:2499-2503.
16. Doherty EA, Doudna JA. (2000). Ribozyme structures and mechanisms. Annu Rev Biochem 69: 597-615.
17. Doh-Ura K, Tateishi J, Sasaki H, Kitamoto T, Sakaki Y. (1989). Pro-leu change at position 102 of prion protein is the most common but not the sole mutation related to Gerstmann-Straussler syndrome. Biochem Biophys Research Commun 163: 974-9.
18. Doh-Ura K, Iwaki T, Caughey B. (2000). Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74: 4894-7.
19. Ehlers B, Diringer H. (1984). Dextran sulphate 500delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65: 1325-30.
20. Enari M, Flechsig E, Weissmann C. (2001). Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proced. Natl Acad Sci 98: 9295-9.
21. Estibeiro P, Godfray J. (2001). Antisense as a neuroscience tool and therapeutic agent. TINS 24: 56-62.
22. Farquhar C, Dickinson A, Bruce M. (1999). Prophylactic potential of pentosan polysulphate in transmissible spongoform encephalopathies. Lancet 353: 117-8.
23. Forloni G, Angeretti N, Chiesa R et al., (1993). Neurotoxicity of a prion protein fragment. Nature 362: 543-546.
24. Gertz H.J, Henkes H, Cervos-Navarro J. (1988). Creutzfeldt-Jakob disease: Correlation of MRI and neuropathologic findings. Neurology 38: 1481-2.
25. Goldfarb L.G, Petersen R.B, Taraton M, et al., (1992). Fatal familial insomnia and familial Creutzfeld - Jakob disease: Disease phenotype determined by a DNA polymorphism. Science 258: 806-8.
26. Griffith JS. (1967). Self-repmication and scrapie. Nature 215: 1043-4.
27. Guenther K, Deacon RM, Perry VH, Rawlins JN. (2001). Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur J Neurosc. 14: 401-9.
28. Harrington MG, Merril CR, Asher DM, Gajdusek DC, (1986). Abnormal protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Eng J Med 315: 279-83.
29. Heppner FL, Musahl C, Arrighy I et al., (2001). Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science, 294: 178-82.
30. Heppner FL, Arrighy I, Kalinke U, Aguzzi A. (2001). Immunity against prions? Trends Mol Med 7: 477-9.
31. Hsiao KK, Baker HF, Crow TJ et al., (1989). Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature 338: 342-5.
32. Hsiao KK, Scott M, Foster D, Groth DF, De Armond SJ, Prusiner SB. (1990). Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250: 1587-90.
33. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harringtom MG. (1996). The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335: 924-30.
34. Ingrosso L, Vetrugno V, Cardone F, Pocchiari M. (2002). Molecular diagnostics of transmissible spongiform encephalopathies. Trends Mol Med 8: 273-80.
35. Ingrosso L, Ladogana A, Pocchiari M. (1995). Congo red prolongs the incubation period in Scrapie-infected Hamsters. J Virol 69: 506-8.
36. Jackson G.S, Collinge J. (2001). The molecular pathology of CJD: Old and new variants. J Clin Pathol: Mol Pathol 54: 393-9.
37. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ. (2000). An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 48: 395-8.
38. Korth C, May BCH, Cohen FE, Prusiner SB. (2001). Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci, 98: 9836-41.
39. Mange A, Milhavet O, McMahon HEM, Casanova D, Lehmann S. (1999). Effect of amphotericin B on wild-type and mutated prion proteins in cultured cells: Putative mechanism of action in transmissible spongiform encephalopathies. J Neurochem 74: 754-62.
40. Manuelidis L, Fritch W, Zaitsev I. (1998). Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet, 352: 456.
41. Massulo C, Macchi G, Xi YG, Pochiari M. (1992). Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis 165: 784-5.
42. Merlini G, Ascari E, Amboldi N, et al., (1995). Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci 92: 2959-63.
43. Milhavet O, Mange A, Casanova D, Lehmann S. (2000). Effect of Congo red on wild-type and mutated prion proteins in cultured cells. J Neurochem 74: 1-9.
44. Mittal S, Farmer P, Kalina P, Kingsley P, Halperin J. (2002). Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 59: 128-4.
45. Montagna P, Cortelli P, Avoni P et al., (1998). Clinical features of fatal familial insomnia: Phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol 8: 515-20.
46. Moore R, Lee IY, Silvermann GL et al., (1999). Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol 292: 797-817.
47. Moore RC, Mastrangelo P, Bouzamondo E et al., (2001). Doppel-induced cerebellar degeneration in transgenic mice. Proc Natl Acad Sci 98: 15288-93.
48. Nicotera P. (2001). A route for prion neuroinvasion. Neuron 31: 345-8.
49. Otto M, Wiltfang J, Schutz E et al., (1998). Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: Prospective case-control strudy. BMJ 316: 577-82.
50. Otto M, Wiltfang J, Cepek L et al., (2002). Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58: 192-7.
51. Palmer MS, Dryden AJ, Hughes JT, Collinge J. (1991). Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352: 340-42.
52. Pan KM, Baldwin M, Nguyen J et al., (1993). Conversion of αhelices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90: 10962-6.
53. Parchi P, Castellani R, Capellari S et al., (1996). Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39: 767-78.
54. Parchi P, Zou W, Wang W et al., (2000). Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci 97: 10168-72.
55. Pepys M.B, Herbert J, Hutchinson WL, et al., (2002). Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417: 254-9.
56. Peretz D, Williamson AR, Kaneko, et al., (2001). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412: 739-43.
57. Perrier V, Wallace A.C, Kaneko K, Safar J, Prusiner SB, Cohen FE. (2000). Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci 97: 6073-8.
58. Pocchiari M, Schmittinger S, Masullo C. (1987). AmphotericinB delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol 8: 219-23.
59. Prinz M, Montrasio F, Klein MA, et al., (2002). Lymph nodal prion replication and neuroinvasion in mice devoid of follicular dendritic cells. Proc Natl Acad Sci 99: 919-24.
60. Priola SA, Caughey B, Caughey WS. (1999). Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies. Current Opinion in Microbiology 2: 563-6.
61. Prusiner SB. (1998). Prions. Proc Natl Acad Sci 95: 13363-83.
62. Prusiner SB. (1982). Novel proteinaceous infectous particles cause scrapie. Science 216: 136-44.
63. Schroter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. (2000). Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 57: 1751-7.
64. Schwaninger M, Winter R, Hacke W, Von Kummer R, Sommer C, Kiessling M. (1997). Magnetic resonance imaging in Creutzfeldt-Jakob disease: Evidence of focal involvement of the cortex. J Neurol Neurosurg Psychiatry 63: 408-16.
65. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R. (2001). A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem. 276: 31479-82.
66. Sigurdsson EM, Brown DR, Daniels M, et al., (2002). Immunization delays the onset of prion disease in mice. Am J Pathol 161: 13-7.
67. Smart JM, Wood A. (2001). Value of fluid-attenuated inversion recovery MR imaging in an unusual case of sporadic Creutzfeldt-Jakob disease. Am J Roentgenol 177: 948-9.
68. Soto C, Saborio GP. (2001). Prions: Disease propagation and disease therapy by conformational transmission. Trends Mol Med 7: 10914.
69. Soto C, Kasczak R.J, Saborio GP, et al., (2000). Reversion of prion protein conformational changes by synthetic β-shett breaker peptides. Lancet 355: 192-7.
70. Steinhoff BJ, Racker S, Herrendorf G, et al., (1996). Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 53: 162-6.
71. Supattapone S, Nguyen HOB, Cohen FE, Prusiner SB, Scott MR. (1999). Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci 96: 14529-34.
72. Supattapone S, Nishina K, Rees JR. (2002). Pharmacological approaches to prion research. Bioch Pharmacol 63: 1383-88.
73. Tagliavini F, McArthur RA, Canciani B, et al., (1997). Effectiveness of antrhracycline against experimental prion disease in syrian hamster. Science 276: 1119-22.
74. Tranchant C, Warter JM. (1998). Gerstmann-Straüssler-Scheinker syndrome. Rev Neurol 2: 152-7.
75. Tranchant C, Geranton L, Guiraud-Chaumeil C, Mohr M, Warter JM. (1999). Basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Neurology 52: 1244-9.
76. Van Everbroeck B, Green AJE, Vanmechelen E, et al., (2002). Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg 73: 79-82.
77. Vrancker AFJE, Frijns CJM, Ramos LMP. (2000). FLAIR MRI in sporadic Creutzfeldt-Jakob disease. Neurology 55: 147-8.
78. Warter JM. (2001). Les maladies humaines familiales à prion. Bull Acad Natle Méd 185: 405-15.
79. Weissmann C, Aguzzi A. (1999). PrP's double causes trouble. Science 286: 914-5.
80. Wells GAH, Scott AC, Johnson CT, et al., (1987). A novel progressive spongiform encephalopathy in cattle. Vet Rec 121: 419-20.
81. Will RG, Zeidler M, Stewart GE. (2000). Diagnosis of new variant Creutzfeldt-Jakob disease. Ann. Neuro 147: 575-82.
82. Will RG, Ironside JW, Zeidler M, et al., (1996). A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347: 921-5.
83. Wong C, Xiong LW, Horiuchi M, et al., (2001). Sulfated glycans and elevated temperature stimulate PrPsc-dependent cell-free formation of protease-resistant prion protein. The EMBO Journal 20: 377-86.
84. Xi YG, Ingrosso L, Ladogana A, Masullo C, Pocchiari M. 1992). Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature 356: 598-601.
85. Zerr I, Pocchiari M, Collins S, et al., (2000). Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnostic of Creutzfeldt-Jakob disease. Neurology 55: 811-5.
86. Zerr I, Bodemer M, Räcker S, et al., (1995). Cerebrospinal fluid concentration of neuron specific endolase in diagnostic of Creutzfeldt-Jakob disease. Lancet 345: 1609-10.
87. Zuljanello L, Kaneko K, Scott M, et al., (2000). Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J Virol 74: 4351-60 replicate without nucleic acid? Nature 214: 764-6.
88. Zuljanello L, Kaneko K, Scott M, et al., (2000). Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J Virol 74: 4351-60 replicate without nucleic acid? Nature 214: 764-6.